IRS1 and breast cancer: Further, IRS1 sensitized BC cells to specific chemotherapeutic drugs, and decreased expression of IRS1 enhanced the resistance of BC cells to paclitaxel, etoposide, and vincristine, but did not change the sensitivity of BC cells to doxorubicin, camptothecin, and daunoblastina (47).